GSK3B and chronic kidney disease: Moreover, according to a large-scale epidemiology study, the incidence of chronic kidney disease and proteinuria in psychiatric patients receiving long term lithium therapy is actually comparable with that in the general population [37], suggesting that the GSK3β inhibitor, lithium, is unlikely toxic to glomerular cells, like podocytes.